论文部分内容阅读
为了探索预防急性髓性白血病复发的有效疗法,作者在普通病房内采用DAV方案,即柔红霉素(DNR)+阿糖胞苷(Ara-C)+表鬼臼毒素(VP16-213)进行强烈缓解诱导治疗,并采用HD-Ara-C/DNR方案,即大剂量阿糖胞苷(HD Ara-C)+DNR进行强烈巩固治疗。诱导治疗:第1疗程(DAV_1)用DNR60mg/M~2,静注,第3-5天,Ara-C100mg/M~2连续静滴,第1-8天,VP16 213100mg/M~2静滴2小时以上,第68天。若第15天骨髓检查示白血病原始细胞超过5%,则进行第2疗程(DAV_1):DNR45mg/M~2,静注,第3-4天,Ara-C100mg/M~2持续静滴,第1-7天,VP16-213100mg/M~2静滴2小时以上,第5-7天。
In order to explore an effective therapy for the prevention of relapse of acute myeloid leukemia, the authors used the DAV regimen in the general ward, namely, daunorubicin (DNR) + cytarabine (Ara-C) + epipodophyllotoxin (VP16-213). The induction therapy was strongly attenuated and the HD-Ara-C/DNR regimen was used, which was a strong consolidation treatment of high-dose cytarabine (HD Ara-C) + DNR. Induction therapy: The first course of treatment (DAV_1) with DNR60mg/M ~ 2, intravenous injection, the first 3-5 days, Ara-C100mg/M ~ 2 continuous intravenous infusion, the first 1-8 days, VP16 213100mg/M ~ 2 intravenous infusion More than 2 hours, 68 days. If the bone marrow examination on the 15th day shows that the leukemic blast cells exceed 5%, then the second course of treatment (DAV_1): DNR45mg/M~2, intravenous injection, the first 3-4 days, Ara-C100mg/M~2 continuous intravenous infusion, the first 1-7 days, VP16-213100mg/M~2 intravenous infusion more than 2 hours, 5-7 days.